Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P170035/S018

ULTRA (samfilcon A) Visibility Tinted Soft Contact Lenses

Bausch and Lomb, Inc., · Decision date Sep 15, 2025

FDA DECISIONP170035/S018

What did the FDA decide?

FDA records P170035/S018 as a supplement to PMA P170035, with the supplement type “30-Day Notice”. The recorded decision is OK30 (30-day notice), dated Sep 15, 2025.

FDA approval order statement

implement concentration control tanks in manufacturing lines to reduce the IPA usage concentration at Bausch + Lombs manufacturing facility located in Rochester, NY
Regulatory pathway
PMA supplement
Supplement type
30-Day Notice
Clinical specialty
Ophthalmic
Decision date
Sep 15, 2025
FDA change category
Process Change - Manufacturer/Sterilizer/Packager/Supplier

FDA source record

Regulatory record facts

Identifier
P170035/S018
Regulatory pathway
PMA supplement
Product code
LPM
Decision code
OK30
Decision date
Sep 15, 2025
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Lenses, soft contact, extended wear.

Product code
LPM
FDA device class
3

For the original device and its historical approval scope, see PMA P170035. Subsequent supplements may change the device or its indications.

FDA decision timeline

  1. P170035 · Original PMA

    Bausch + Lomb Ultra (samfilcon A) Contact Lenses

  2. P170035/S018 received

    Application receipt date recorded by FDA.

  3. P170035/S018 · FDA decision

    30-Day Notice

  4. P170035/S019 · Related supplement

    Bausch + Lomb Ultra (Samfilcon A) Visibly Tinted (Soft) Contact Lenses

  5. P170035/S021 · Related supplement

    Bausch + Lomb Ultra (samfilcon A) Contact Lenses

Timeline entries are records held by MedtechLedger for P170035. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P170035

Product / regulatory recordCompanyPathwayDecision dateSource
Bausch and Lomb, Inc.,PMA approvalApr 30, 2018FDA
Bausch and Lomb, Inc.,PMA supplementDec 4, 2025FDA
Bausch and Lomb, Inc.,PMA supplementSep 14, 2026FDA

Explore the linked device profile

Other records with product code LPM

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Bausch and Lomb, Inc.,

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
1400 N. Goodman St., Rochester, NY, 14609

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records